PhaseBio Pharmaceuticals Cost of Revenue

Cost of Revenue of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending March 30, 2021 was $474 Thousand (a 38.6% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 731.58%
  • Annual Cost of Revenue for 2018 was $105 Thousand (a 9.38% increase from previous year)
  • Annual Cost of Revenue for 2017 was $96 Thousand (a 4.35% increase from previous year)
  • Twelve month Cost of Revenue ending March 30, 2021 was $928 Thousand (a 82.68% increase compared to previous quarter)
Trailing Cost of Revenue for the last four month:
30 Mar '21 30 Dec '20
$928 Thousand $508 Thousand
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of PhaseBio Pharmaceuticals

Most recent Cost of Revenueof PHAS including historical data for past 10 years.

Interactive Chart of Cost of Revenue of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.47
2020 $0.34 $0.06 $0.06 $0.05
2018 $0.11
2017 $0.1
2016 $0.09

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.